Your browser is no longer supported. Please, upgrade your browser.
Settings
AKTX Akari Therapeutics, Plc daily Stock Chart
AKTX [NASD]
Akari Therapeutics, Plc
Index- P/E- EPS (ttm)-1.54 Insider Own20.51% Shs Outstand9.92M Perf Week-26.88%
Market Cap148.70M Forward P/E- EPS next Y-4.56 Insider Trans0.00% Shs Float3.37M Perf Month125.41%
Income-18.10M PEG- EPS next Q-0.58 Inst Own34.00% Short Float0.42% Perf Quarter108.19%
Sales- P/S- EPS this Y71.00% Inst Trans0.06% Short Ratio0.02 Perf Half Y64.91%
Book/sh2.90 P/B5.17 EPS next Y-44.80% ROA-33.20% Target Price19.75 Perf Year-
Cash/sh4.45 P/C3.37 EPS next 5Y- ROE-44.80% 52W Range6.22 - 22.20 Perf YTD112.93%
Dividend- P/FCF- EPS past 5Y38.70% ROI- 52W High-32.48% Beta-8.73
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low141.00% ATR2.67
Employees15 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)53.76 Volatility16.55% 23.24%
OptionableNo Debt/Eq0.00 EPS Q/Q-228.50% Profit Margin- Rel Volume0.40 Prev Close15.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume708.38K Price14.99
Recom2.00 SMA200.39% SMA5050.70% SMA20066.86% Volume282,550 Change-0.07%
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Apr-27-17 06:47AM  Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled Akaris Coversin matches Soliris in Phase II GlobeNewswire -8.87%
Apr-24-17 12:33PM  Is This Why Akari Therapetuics PLC Is Falling Today? Motley Fool -14.68%
07:25AM  Akari Therapeutics stock rises 10% on positive mid-stage trial results MarketWatch
07:15AM  Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets GlobeNewswire
Apr-21-17 05:31AM  Akari Therapeutics (AKTX) Shares March Higher, Can It Continue? Zacks +25.23%
Apr-19-17 03:36PM  Harry Boxers momentum stocks to watch: 3 biotechs, 1 retailer MarketWatch -7.88%
Apr-03-17 10:22AM  Company News for April 03, 2017 Zacks +5.78%
09:30AM  Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News Accesswire
07:00AM  Akari Therapeutics to Present at the Jefferies Complement Symposium GlobeNewswire
Mar-31-17 12:44PM  Will Akari Therapeutics (AKTX) Continue to Surge Higher? Zacks +58.51%
10:30AM  How Akari Therapeutics Is Putting Itself on the Map 24/7 Wall St.
10:27AM  Akari Gets Fast Track Status for Coversin Drug Investopedia
10:27AM  Akari Gets Fast Track Status for Coversin Drug at Investopedia
05:20AM  CORRECTED: Akari Pharma up 13% after FDA puts one of its treatments on fast track MarketWatch
05:20AM  CORRECTED: Akari Pharma up 13% after FDA puts one of its treatments on fast track at MarketWatch
Mar-30-17 04:02PM  Akari Therapeutics Announces FDA Fast Track Designation For Coversin GlobeNewswire +5.02%
Mar-17-17 07:00AM  Akari Therapeutics Announces R&D Day on April 24, 2017 GlobeNewswire +7.86%
Mar-07-17 07:00AM  Akari Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire
Jan-31-17 07:00AM  Akari Therapeutics to Attend Upcoming Investor Conferences in February GlobeNewswire +17.65%
Jan-04-17 07:00AM  Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans GlobeNewswire
Jan-03-17 07:00AM  Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH GlobeNewswire +6.53%
Dec-12-16 07:39PM  Is Akarti Therapeutics PLC (ADR) (AKTX) A Good Stock To Buy? at Insider Monkey +5.85%
Dec-05-16 11:33AM  Akari Therapeutics Plc :AKTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
07:00AM  Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins GlobeNewswire
Nov-11-16 07:00AM  Akari Therapeutics to Attend Upcoming Investor Conferences In November GlobeNewswire
Nov-03-16 08:00AM  Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology GlobeNewswire
Oct-14-16 07:00AM  Akari Therapeutics Appoints New Members to its Board of Directors GlobeNewswire +5.93%
Sep-16-16 12:18PM  Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City GlobeNewswire
Sep-12-16 07:15AM  Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Aug-04-16 07:00AM  Akari Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire -7.59%
Jul-13-16 07:59AM  Akari Therapeutics Gets Regulatory Approval To Conduct Phase 2 Study In Paroxysmal Nocturnal Hemoglobinuria
07:00AM  Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Jul-12-16 07:00AM  Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Jul-11-16 06:15AM  Coverage initiated on Akari Therapeutics by Chardan Capital Markets -8.14%
Jul-06-16 07:00AM  Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin GlobeNewswire
Jun-30-16 05:05PM  AKARI THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote
Jun-15-16 07:00AM  Akari Therapeutics to Present at the JMP 2016 Life Sciences Conference GlobeNewswire
Jun-06-16 02:30PM  Akari Therapeutics Plc :AKTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-26-16 07:00AM  Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference GlobeNewswire
May-23-16 11:17AM  Akari Therapeutics Gets Positive Opinion For Orphan Drug Status For Coversin In EU For Guillain Barré Syndrome Treatment
07:10AM  Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome GlobeNewswire
May-19-16 07:30AM  Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated GlobeNewswire
May-17-16 01:04PM  AKARI THERAPEUTICS PLC Financials
May-12-16 04:13PM  AKARI THERAPEUTICS PLC Files SEC form 10-Q, Quarterly Report
04:05PM  Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome GlobeNewswire
Apr-26-16 04:35PM  AKARI THERAPEUTICS PLC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-14-16 07:30AM  Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology GlobeNewswire
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation C5 complement inhibitor that is in Phase Ib clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.